Free provider profile
RACHEL STEERE, D.O.
NPI 1588081673
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2019-06-30.
16 BLOSSOM ST, BOSTON, MA, 02114
617-726-2712
3 practice locations listed
Enumerated 2014-03-26
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 3 practice locations listed — multi-site footprint.
- — Record last updated 7 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
730
Medicare patients
56
Part D drug cost
$51,201
Brand-name share
4.8%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Buprenorphine-Naloxone (Buprenorphine Hcl/Naloxone Hcl) | 98 | $15,170 |
| Trintellix (Vortioxetine Hydrobromide) | 11 | $7,727 |
| Belsomra (Suvorexant) | 13 | $5,679 |
| Varenicline Tartrate (Varenicline Tartrate) | 17 | $4,485 |
| Mirtazapine (Mirtazapine) | 45 | $1,133 |
| Clonazepam (Clonazepam) | 108 | $1,103 |
| Gabapentin (Gabapentin) | 48 | $608 |
| Prazosin Hcl (Prazosin Hcl) | 12 | $593 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
2024231 sessions · 28 patients · $244,703
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.